Results 41 to 50 of about 63,834 (200)

Twenty-six years of HIV science: an overview of anti-HIV drugs metabolism

Brazilian Journal of Pharmaceutical Sciences, 2011
From the identification of HIV as the agent causing AIDS, to the development of effective antiretroviral drugs, the scientific achievements in HIV research over the past twenty-six years have been formidable.
Carolina Horta Andrade, Lenis Medeiros de Freitas, Valéria de Oliveira   +2 more
doaj   +1 more source

Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study

JMIR Public Health and Surveillance, 2023
BackgroundEmerging HIV drug resistance caused by increased usage of antiretroviral drugs (ARV) could jeopardize the success of standardized HIV management protocols in resource-limited settings.
Hongli Chen, Jingjing Hao, Jing Hu, Chang Song, Yesheng Zhou, Miaomiao Li, Jin Chen, Xiu Liu, Dong Wang, Xiaoshan Xu, Peixian Xin, Jiaxin Zhang, Lingjie Liao, Yi Feng, Dan Li, Stephen W Pan, Yiming Shao, Yuhua Ruan, Hui Xing   +18 more
doaj   +1 more source

Factors Influencing the Binding of HIV‐1 Protease Inhibitors: Insights from Machine Learning Models

ChemMedChem, Accepted Article.
HIV‐1 protease inhibitors are crucial for antiviral therapies targeting acquired immunodeficiency syndrome (AIDS). Hundreds of HIV‐1 protease complexes with various ligands have been resolved and deposited in the Protein Data Bank. However, binding affinity measurements for these ligands are not always available.
Yaffa Shalit, Inbal Tuvi-Arad
wiley   +1 more source

Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). [PDF]

PLoS ONE, 2013
A major concern with using antiretroviral (ARV)-based products for HIV prevention is the potential spread of drug resistance, particularly from individuals who are HIV-infected but unaware of their status.
Urvi M Parikh, Photini Kiepiela, Shayhana Ganesh, Kailazarid Gomez, Stephanie Horn, Krista Eskay, Cliff Kelly, Barbara Mensch, Pamina Gorbach, Lydia Soto-Torres, Gita Ramjee, John W Mellors, MTN-009 Protocol Team, IPTc Taskforce   +13 more
doaj   +1 more source

Human Transbodies to Reverse Transcriptase Connection Subdomain of HIV-1 Gag-Pol Polyprotein Reduce Infectiousness of the Virus Progeny

Vaccines, 2021
HIV-1 progeny are released from infected cells as immature particles that are unable to infect new cells. Gag-Pol polyprotein dimerization via the reverse transcriptase connection domain (RTCDs) is pivotal for proper activation of the virus protease (PR ...
Watee Seesuay, Siratcha Phanthong, Jaslan Densumite, Kodchakorn Mahasongkram, Nitat Sookrung, Wanpen Chaicumpa   +5 more
doaj   +1 more source

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick‐Sanders, Randa Hareedy, Louise Harkness, Claudia Leemereise, Kjersten Offenbecker, Christina Donatti, Darin B. Brimhall, Christian Schwabe, Craig Boyle, Michael A. Hassman, Steve Knowles, Ronald D'Amico, William R. Spreen   +16 more
wiley   +1 more source

Lower genetic variability of HIV-1 and antiretroviral drug resistance in pregnant women from the state of Pará, Brazil

BMC Infectious Diseases, 2017
Background The present study aimed to describe the genetic diversity of HIV-1, as well as the resistance profile of the viruses identified in HIV-1 infected pregnant women under antiretroviral therapy in the state of Pará, Northern Brazil.
Luiz Fernando Almeida Machado, Iran Barros Costa, Maria Nazaré Folha, Anderson Levy Bessa da Luz, Antonio Carlos Rosário Vallinoto, Ricardo Ishak, Marluisa Oliveira Guimarães Ishak   +6 more
doaj   +1 more source

Decoding RNA–Protein Interactions: Methodological Advances and Emerging Challenges

Advanced Genetics, EarlyView.
This review provides a comprehensive comparison of RNA‐ and protein‐centric methodologies for investigating RNA–protein interactions, emphasizing their respective advantages, limitations, and suitable applications. It highlights recent technological innovations, outlines strategic method selection criteria, and addresses key challenges.
Wenkai Yi, Jian Yan
wiley   +1 more source

Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia.

PLoS ONE, 2013
BackgroundMulti-nucleos(t)ide resistance (MNR) mutations including Q151M, K65R mutations, and insertion at codon 69 of HIV-1 reverse transcriptase coding region may confer resistance to all molecules of nucleos(t)ide reverse transcriptase inhibitors ...
Janin Nouhin, Yoann Madec, Nicole Ngo-Giang-Huong, Laurent Ferradini, Eric Nerrienet   +4 more
doaj   +1 more source

Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase

Frontiers in Molecular Biosciences, 2022
Reverse transcriptase (RT) from the human immunodeficiency virus continues to be an attractive drug target for antiretroviral therapy. June 2022 will commemorate the 30th anniversary of the first Human Immunodeficiency Virus (HIV) RT crystal structure ...
Kathleen M. Frey, Nicole Bertoletti, Albert H. Chan, Joseph A. Ippolito, Mariela Bollini, Krasimir A. Spasov, William L. Jorgensen, Karen S. Anderson, Karen S. Anderson   +8 more
doaj   +1 more source